NGM Biopharmaceuticals Inc reports results for the quarter ended in December - Earnings Summary

NGM Biopharmaceuticals

01/03/2023 01:14

* NGM Biopharmaceuticals Inc  NGM.OQ  reported a quarterly
adjusted loss of 45 cents​​ per share for the quarter ended in
December. The mean expectation of six analysts for the quarter
was for a loss of 51 cents per share.
    * Revenue fell 13.3% to $18.18 million from a year ago;
analysts
expected $6.76 million. 
    * NGM Biopharmaceuticals Inc's reported EPS for the quarter
was a
loss of 45 cents​.
    * The mean earnings estimate of analysts was unchanged in
the last
three months.​ 
    * In the last 30 days there have been no negative revisions
of
earnings estimates 
    * NGM Biopharmaceuticals Inc shares had fallen by 9.2% this
quarter.
    * The company reported a quarterly loss of $36.44 million.
    * Wall Street's median 12-month price target for NGM
Biopharmaceuticals Inc is $5.00 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 3 "strong buy" or "buy," 3
"hold" and no "sell" or "strong sell." 

This summary was machine generated from Refinitiv data March 1
at 01:14 a.m.  ​All figures in US dollars unless otherwise
stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Dec. 31 2022      -0.51          -0.45          Beat
 Sep. 30 2022      -0.59          -0.59          Met
 Jun. 30 2022      -0.55          -0.59          Missed
 Mar. 31 2022      -0.46          -0.42          Beat